Guide

NOOH letters, explained

A NOOH letter — Notice of Opportunity for Hearing — is the document FDA sends a clinical investigator when the explanation offered in response to a NIDPOE letter has not resolved the matter. It is the second formal step in disqualification under 21 CFR 312.70, and it moves the proceeding from an exchange of explanations to a regulatory hearing.

Where it sits in the process

1. NIDPOE. FDA notifies the clinical investigator that it has information the investigator repeatedly or deliberately failed to comply with the regulations, or submitted false information, and offers an opportunity to explain — in writing or at an informal conference.

2. NOOH. If the explanation is not accepted, the center offers the clinical investigator an opportunity for a regulatory hearing under 21 CFR part 16. The NOOH sets out FDA’s allegations and the evidence it relies on, and tells the investigator how, and by when, to request the hearing.

3. Hearing, or none. The clinical investigator may request the hearing, may decline it, or may not respond. If no hearing is requested, FDA decides on the record it has.

4. Decision. The Commissioner (in practice, the center on the Commissioner’s behalf) decides whether the clinical investigator is disqualified. A consent agreement can end the matter at any stage.

What a NOOH letter contains

A NOOH is usually the most detailed document in a disqualification file. It restates the conduct alleged in the NIDPOE, explains why the clinical investigator’s response did not resolve it, and sets out the specific regulatory provisions at issue — typically failures under 21 CFR part 312 (conducting the study, informed consent, case histories, control of the investigational drug, supervision) or under part 50 and part 56. Because it answers the investigator’s explanation point by point, it is often more informative than the NIDPOE about what actually happened.

How proceedings end

Three ways, the same three as after a NIDPOE:

Not disqualified. The hearing or the record did not support disqualification, or the clinical investigator’s assurances were found adequate. The NIDPOE and NOOH still exist as documents; the outcome is what changed.

Consent agreement. The clinical investigator accepts restrictions on future research, or gives specified assurances, in lieu of full disqualification. In the public record this shows as “restricted” and, once the terms are met, “restrictions removed”. The proceeding stays on the record.

Disqualified. In the words of 21 CFR 312.70(b), the clinical investigator is “not eligible to receive test articles” and is “ineligible to conduct any clinical investigation that supports an application for a research or marketing permit for products regulated by FDA”. FDA notifies the investigator, the sponsor of any investigation in which the investigator was named, and the reviewing IRB. FDA may then examine each investigation the investigator took part in and decline to rely on the data.

A disqualified clinical investigator can later be reinstated if FDA is satisfied by adequate assurances that the investigator will comply. Reinstatement, like the proceeding itself, is part of the record.

What a NOOH on a record means for a sponsor

A NOOH means the clinical investigator’s explanation was heard and did not resolve FDA’s concern. It is a stronger signal than a NIDPOE alone, and it comes with the most specific account of the conduct that exists. Three practical points:

Read the letter, then read the outcome. A NOOH followed by “not disqualified” and one followed by disqualification are different facts. A NOOH with no recorded outcome usually means the proceeding is still open.

Proceedings run for years. The dates on the NIDPOE, the NOOH and the decision can span two or more years; a candidate clinical investigator can be mid-proceeding at selection time without being on any list.

The decision is the sponsor’s. A restricted or reinstated clinical investigator may lawfully work, under conditions the sponsor should know before engagement. Where a record shows this history, the options are to ask for the site’s responses and corrective action plans, to visit before signing, or to choose a site without it.

Questions this page answers

What is a NOOH letter?

NOOH stands for Notice of Opportunity for Hearing. It is the letter FDA sends a clinical investigator when the explanation offered in response to a NIDPOE letter has not resolved the matter, offering a regulatory hearing under 21 CFR part 16 before FDA decides whether to disqualify the investigator.

What is the difference between a NIDPOE and a NOOH?

The NIDPOE (Notice of Initiation of Disqualification Proceedings and Opportunity to Explain) opens the proceeding and invites an explanation. The NOOH follows if that explanation is not accepted, and offers a formal hearing. Every NOOH was preceded by a NIDPOE; most NIDPOEs do not lead to a NOOH.

Does a NOOH mean the clinical investigator is disqualified?

No. It means FDA has not accepted the clinical investigator’s explanation and is proceeding toward a decision. The proceeding can still end in a finding that the investigator is not disqualified, in a consent agreement with restrictions, or in disqualification.

Is a sponsor told when one of its clinical investigators receives a NOOH?

Not as a rule. FDA formally notifies sponsors when a clinical investigator is disqualified. During the proceeding, learning of it depends on the investigator, or on the sponsor checking the record.

Can a disqualified clinical investigator be reinstated?

Yes. FDA can reinstate a clinical investigator who provides adequate assurances of future compliance. Reinstatement is recorded alongside the original proceeding, and both remain part of the investigator’s history.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.